PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Otava Ltd

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Otava Presents Liver X Receptor β Agonists Library - OTAVA Ltd offers Liver X receptor (LXR) focused library which is targeted towards Liver X receptor β and comprises 553 compounds. This library includes drug-like compounds only - OtavaChemicals.com
Otava Presents Liver X Receptor β Agonists Library

 

NewswireToday - /newswire/ - Toronto, Ontario, Canada, 2014/03/20 - OTAVA Ltd offers Liver X receptor (LXR) focused library which is targeted towards Liver X receptor β and comprises 553 compounds. This library includes drug-like compounds only - OtavaChemicals.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Liver X receptors (LXRs) are ligand-activated transcription factors that belong to nuclear receptor superfamily. LXRs function as sterol sensors protecting cells from cholesterol overload by stimulating reverse cholesterol transport and activating its conversion to bile acids in the liver. Since LXRs play important role in lipid and cholesterol metabolism these receptors may be involved in the development of metabolic diseases such as hyperlipidemia and atherosclerosis.

LXR agonists were shown to be effective for treatment of murine models of atherosclerosis, diabetes, anti-inflammation, and Alzheimer’s disease. Also it was demonstrated that LXR agonists suppress the proliferation of prostate cancer and breast cancer cells. Unfortunately, known ligands possess undesirable side effects inducing lipogenesis and hypertriglyceridemia by transactivating genes involved in fatty acid biosynthesis. Therefore, development of novel LXR agonists is very important in modern drug design.

OTAVA Ltd (otavachemicals.com) offers Liver X receptor (LXR) focused library which is targeted towards Liver X receptor β and comprises 553 compounds. This library includes drug-like compounds only.

The library was designed by performing molecular docking of OTAVA’s collection of drug-like compounds in crystal structure of human LXRβ (PDB ID: 1UPV). The most important polar interaction of a ligand and LXRβ is a hydrogen bond with His435. This bond is observed in many LXR receptor-ligand complexes, including those with steroid compounds. The presence of this hydrogen bond has been used as criteria for filtering docking results in order to identify the most consistent binding modes. The complexes obtained after filtering were taken for visual inspection to exclude ligands displaying inappropriate binding.

This library provides an excellent basis for development of novel therapeutics for lipid disorders, atherosclerosis, chronic inflammation, autoimmunity, cancer and neurodegenerative diseases. .

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Otava Ltd

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Otava Presents Liver X Receptor β Agonists Library

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: Andrey Dmytrenko - OtavaChemicals.com 
416-549-8030 info[.]otavachemicals.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Otava Ltd securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Otava Ltd / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  NAKIVO, Inc.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)